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Accepted 15 December 2015The introduction of selective serotonin reuptake inhibitors has gradually changed the borders of the
major depression disease class. Anhedonia was considered a cardinal symptom of endogenous depres-
sion, but the potential of selective serotonin reuptake inhibitors to treat anxiety disorders has increased
the relevance of stress-induced morbidity. This shift has led to an important heterogeneity of current
major depressive disorder. The complexity can be disentangled by postulating the existence of two dif-
ferent but mutually interacting neuronal circuits regulating the intensity of anhedonia (lack of pleasure)
and dysphoria (lack of happiness). These circuits are functionally dominated by partly closed limbic (reg-
ulating misery-fleeing behaviour) and extrapyramidal (regulating reward-seeking behaviour) cortico-
striato-thalamo-cortical (CSTC) circuits. The re-entry circuits include the shell and core parts of the
accumbens nucleus, respectively. Pleasure can be considered to result from finding relief from the hyper-
motivation to exhibit rewarding behaviour, and happiness from finding relief from negative or conflicting
circumstances. Hyperactivity of the extrapyramidal CSTC circuit results in craving, whereas hyperactivity
of the limbic system results in dysphoria.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In psychiatry, the term anhedonia (Greek: am- an-, ‘‘without”
+ ήdomή he¯done¯, ‘‘pleasure”) describes the inability to experience
pleasure from usually enjoyable activities, such as exercise, hob-
bies, sexual activities, or social interactions [1]. In the 1960s and
1970s, anhedonia was considered a core symptom of ‘‘endoge-
nous” depression. It was also included as a main criterion for the
diagnosis of major depressive disorder (MDD) with melancholia,
according to the third edition of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-III), published in 1980 [2,3].
MDD with melancholia was considered to be a specific subtype
of depression known to respond preferentially to biological
treatment, which in those days included tricyclic antidepressant
drugs and electroconvulsive therapy [3].
Shortly after publication of the DSM-III, selective serotonin
reuptake inhibitors (SSRIs) were marketed, changing the borders
of the MDD disease class. SSRIs appear to be therapeutically active
in certain anxiety disorders, such as panic disorder and obsessive–
compulsive disorder [4]. This efficacy indicates that the serotonin
system is very involved in stress and worrying; more accurately,drugs that interfere with the activity of the serotonergic system
can be used to treat disorders that are accompanied by stress
reactions and cognitive anxious and/or depressed symptoms.
Symptoms of anxiety and depression commonly co-occur [5], and
at least some evidence has been found for shared genetic
aetiologies between these conditions [6]. Moreover, experiments
with ‘serotonergic’ interventions led to the defining of a new
subtype of depression, designated as ‘anxiety/aggression-driven
depression’ [7].
The potential of SSRIs for treatment of both MDD and anxiety
disorders resulted in a broadening of the depression concept and
probably induced considerable heterogeneity within the class of
disorders currently referred to as MDD. However, attempts to
cluster this variety of symptoms in separate classes of depressive
disorder have not been very fruitful [8]. Melancholic symptoms
(including pervasive anhedonia) remain key features in distin-
guishing an ‘‘endogenous” subtype from other forms of depression
[2,9]. Using specific symptoms to discriminate between additional
and/or overlapping subtypes seems to be pointless.
In our opinion, the problem can better be approached from the
other direction, starting with the biological basis of subsets of
depressive symptoms. We suggest taking a possible dysfunction
of specific brain structures as the starting point for defining differ-
ent components of depression that may differentially respond to
different (pharmacological and/or psychological) treatments.
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ronal circuits regulating different aspects of depressive disorder
and propose to distinguish two, mutually interacting components
of depression. According to one component, depression can be
considered to be a ‘worrying’ disorder, characterized by many cog-
nitive symptoms, including feelings of hopelessness and negative
expectations. According to the other component, depression can
be considered to be a ‘lust’ disorder, characterized by loss of energy
and motivation, as well as by anhedonia. The symptoms of these
two components largely overlap and they can possibly best be con-
sidered as the two theoretical endpoints of a depressive disease
continuum. In addition, they interact with each other in a yin-
and-yang fashion. However, considering depression as consisting
of two such components may offer interesting starting points for
research into (e.g., neuroendocrine and neuroimmunological)
biomarkers of depression and the interaction of brain structures
during drug treatment and psychotherapy. To facilitate a clear
description of the neuronal circuits involved, we will first briefly
describe a specific model for the cerebral organization of the beha-
vioural response systems.The behavioural response systems
Basic starting points
In its most essential form, behaviour can be considered as an
adaptive reaction of the organism to important stimuli from the
environment. Within the brain, input from the senses (in humans,
also cognitions) is transformed into a specific, partly behavioural,
output as a reaction to the conditions within the individual’s
biosphere.
This capability to respond to environmental circumstances
must be very ancient. Even the most primitive freely moving
animals living in the oceans at the beginning of the Cambrian
explosion over 540 mya must have been capable of feeding,
fighting, hiding, and mating in order to survive as individuals
and as a species. Therefore, their primitive brains must have
been able to regulate these processes. We have recently
described the evolution of the circuits controlling reward-
seeking and misery-fleeing behaviours [10]. The earliest
vertebrates had a forebrain with a quite modern extrapyramidal
system that could induce the above behaviours by giving direct
output to motor control centres within the brainstem. These ani-
mals still lacked neocortical regulatory control structures. The
input of this extrapyramidal system was predominantly olfac-
tory. The activity of the extrapyramidal system was regulated
by monoaminergic fibres coming from the lower diencephalon
and upper brainstem. These fibres reinforced appetitive-seeking
behaviour or flight behaviour resulting from negative input.
More recently, vertebrates developed limbs and invaded the con-
tinents, a lifestyle that required numerous new skills. This acqui-
sition resulted in the further development of a large forebrain
with its neo-cortical and neo-subcortical structures for ade-
quately processing complex input and generating adequate
(and also far more complex) output [10,11]. Nevertheless, the
primary functions were probably retained within the brainstem,
diencephalon and subcortical forebrain (mainly ventral striatum,
amygdala, and hippocampus).
These considerations make it plausible that in modern humans,
the aforementioned basic emotional functions are also primarily
regulated by embryological ‘early’ developed parts of the nervous
system within the forebrain, primarily the archipallium (hip-
pocampus) and archistriatum (nuclear amygdala), with only parts
of the paleopallium [12]. The limbic areas arising from these early
structures are probably still primarily responsible for the emo-
tional response type in the adult brain.Emotional response regulation
A suitable model for the regulation of the emotional response
can be derived from the paper of Terence and Mark Sewards
[13]. According to their model, the control centre for emotional
response types like sexual desire, hunger, thirst, fear, nurturance,
sleep-need drives and power-dominance drives is the hypothalamus.
The output of the hypothalamus proceeds along three channels.
The first route projects via the thalamus to the cortex, including
a pathway that contributes to the perception of emotion and one
for the initiation and planning of cognitive and motor responses
(drives). The second output pathway is a projection at least partly
via the periaqueductal grey (PAG) to several brainstem nuclei,
including nuclei that regulate the autonomic components of the
emotional response (e.g., increased circulation and respiration).
The PAG also activates the serotonergic raphe nuclei, the adrener-
gic locus coeruleus complex, and the dopaminergic ventral
tegmental area [13–16]. From these nuclei, projections pass back
to the hypothalamus (e.g., regulating hypophysiotropic hormones)
and through the medial forebrain bundle to the forebrain (activat-
ing the frontal cortex). The PAG also constitutes an important input
structure generating signals to the emotional forebrain [17]. Apart
from hormone release mediated through various brainstem nuclei,
a third direct hypothalamic projection system regulates the endo-
crine component of the emotional response, enabling adaptation of
the milieu interne, or correction of a possible misbalance. The
hypothalamus also exerts a receptor function for various sub-
stances in the circulating blood [18].
This model corresponds to a significant extent with the model
of Mario Liotti and Jaak Panksepp [19]. However, they follow a dif-
ferent approach, describing seven emotional systems for seeking,
rage, fear, panic (separation distress and social bonding), care (nurs-
ing and empathy), lust (sexual love), and play (joy and curiosity),
which are not all regulated by the autonomic hypothalamus.
Within the context of this article, the first three systems deserve
a more detailed description.
The appetitive motivation seeking system stimulates the organ-
ism to acquire the many things needed for survival [19]. This moti-
vation is coupled to a reward feeling that can—but not necessarily
does—result from these activities. The nature of the specific
rewards is of a lesser importance; the system works equally well
for seeking food, water, warmth, and illicit drugs, as well as for
social goals like sexual gratification, maternal engagement, and
playful entertainment. The system promotes interest, curiosity,
and desire for engagement with necessary daily life activities
[19]. The process of reward pursuing consists of at least three psy-
chological components: learning to value (attentive salience),
incentive salience or ‘wanting’, and experiencing pleasure resulting
in ‘liking’ [20,21]. The first component is believed to be addressed
by the amygdala [22,23]. The amygdala can ‘learn’ to appreciate
sensory appetitive information within the context of external and
internal circumstances and to initiate a proper response. The sec-
ond component is regulated by mesocorticolimbic mechanisms
[20], with a central role for the nucleus accumbens (NAcb)
[24,25]. Important neural substrates for this system are dopamin-
ergic mesolimbic and mesocortical projections coming from the
ventral tegmental area [26,27]. The latter also determines the
physical link between the possibility of experiencing pleasure
and the development of addiction [28].
The amygdala additionally takes a central position with respect
to valuing aversive stimuli [22,23], playing a critical role in anxiety
and aggression. The anger-promoting rage system is associated
with irritation and frustration [19]. In this system, the emotional
circuit is stimulated by projections between the medial amygdala
and the medial hypothalamus via the stria terminalis [29]. Neurons
also project reciprocally between specific parts of the PAG in the
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organized in a fashion parallel to the rage system, in which both
the amygdala and the PAG project to the medial hypothalamus
[30,31]. Activity within this system can lead to freezing or flight
behaviour. Sustained fear (anxiety) is also mediated by the amyg-
dala, but follows a slightly different anatomical route [30] and links
the fear and stress systems.
Taken together, the regulation of the described forms of emo-
tional output can be summarized and simplified into the scheme
in Fig. 1. The hypothalamus can be considered one of the principle
control centres for emotional (non-behavioural) output (especially
gratification, fear, and aggression-driven). As explained above, the
hypothalamus itself receives a stimulating input function from the
amygdala, among other regions. The amygdala is responsible for
the initiation of a suitable response type. In this process of initiat-
ing the emotional response, the amygdala is inhibited by the med-
ial prefrontal cortex [32–34]. This scheme describes the process of
response selection, but another mechanism is regulating the level
of motivation to exhibit the selected response type.Limbic regulatory system
The abovementioned model (Fig. 1) concentrates the controller
role of the complex emotional response within the hypothalamus
and its initiator function within the amygdala [35]. The amygdala
consists of a heterogeneous group of nuclei and cortical regions
and is divided into cortical (basolateral) and ganglionic (centrome-
dial) sections [22,36,37]. The various nuclei differ in the number
and type of brain areas to which they are connected (Fig. 2). Apart
from extensive connectivity with a variety of cortical areas [36],
the various parts of the complex are mutually massively connected
with each other [36,37]. Nevertheless, it is possible to consider the
centromedial part as an output channel to the diencephalon and
brain stem, while the basolateral part is more easily regarded as
an input channel for cortical information (Fig. 2). Moreover, the
amygdaloid complex has widespread connectivity with many sub-
cortical regions [36], including the dorsal and ventral striatum, the
bed nucleus of the stria terminalis, and the basal forebrain nuclei.
The centromedial amygdala is continuous with the extended
amygdala, which is in turn continuous through the bed nucleus














Fig. 1. Simplified model for the regulation of emotional response. The hypothalamus is c
response. In this depiction, the amygdala represents all limbic structures involved in emextended amygdala takes a position to the allocortex (olfactory
cortex and hippocampus) that is similar to that which the
neocortex takes to the striatum [39]. This idea can be extended
to distinguishing limbic and extrapyramidal basal ganglia. The cen-
tromedial amygdala, proper extended amygdala, bed nucleus of
the stria terminalis, and the shell of the NAcb form the limbic basal
ganglia, with a function for the limbic cortex that reflects that of
the extrapyramidal basal ganglia for the rest of the neocortex
(Fig. 3).A neurobiological model of depression
Investigations using in vivo neuroimaging methods have
demonstrated that the depressive syndrome is probably best con-
ceptualized as a disorder rooted in a dysfunction of neuronal cir-
cuits [40]. This formulation means that a depressive episode
should be considered to result from failed network regulation
under circumstances of cognitive, emotional, or somatic stress
[41]. Moreover, depression is not only caused by the failure of
one discrete network but also involves the inability of the remain-
ing system to maintain homeostasis. Mayberg and co-workers
developed a limbic–cortical dysregulation model to explain neu-
roimaging findings in three behavioural states: baseline depressed,
post-treatment (medication, cognitive therapy, placebo, surgery),
and transiently induced sadness [41,42]. A key structure in their
model is the infralimbic subgenual anterior cingulate cortex
(Cg25). Activity in this area increases with sad mood and decreases
following response to several antidepressant biological treatments.
An important limitation of their work is the use of SSRIs for
their ‘post-treatment with medication’ condition. However, SSRIs
may have dissimilar antidepressant effects in comparison to tri-
cyclic antidepressants [43]. As described in the introduction, SSRIs
more specifically have efficacy in many stress disorders [4]. Selec-
tive norepinephrine uptake inhibitors are devoid of this activity
[44].
Based on the integration of five current theories that explain
how dysfunction of neurobiological processes may result in the
development of a depressive mood disorder, we have developed
a different model [45]. Integrating the amine, biorhythm, neuroen-
docrine, neuroimmunological, and kindling hypotheses of depres-















onsidered to be the principle controller and the amygdala the initiator of emotional
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Fig. 2. Connections of the four sections of the amygdaloid nucleus. The various amygdaloid nuclei differ in the areas to which they are connected (adapted from Ref. [37],
reproduced with permission of the author).
caudate head
















Fig. 3. Position of the limbic basal ganglia (centromedial amygdala, extended amygdala, bed nucleus of the stria terminalis, and nucleus accumbens shell) relative to the
extrapyramidal basal ganglia and hippocampus.
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lack of energy and pleasure, and as a ‘worrying’ or ‘concern’ disor-
der, characterized by feelings of uselessness and hopelessness. Thefirst type of depression can be associated with dysfunction of
brainstem, diencephalon, and extrapyramidal basal ganglia, and


















Fig. 5. Stimulation of the core and shell of the nucleus accumbens. (Adapted from
Ref. [49], reproduced with permission of the author). VTA = ventral tegmental area
(dopaminergic); LC = locus coeruleus (adrenergic).
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plex. According to our model, subcortical structures play a domi-
nant role in generating pathological mood conditions.
Role of the extrapyramidal basal ganglia
The ‘extrapyramidal system’ is often mainly associated with
motor activity but also regulates other behavioural responses.
The first station of this circuit is formed by the striatum, which
consists of three parts that correspond to three parallel divisions
of the extrapyramidal system (Fig. 4): the caudate nucleus
(cognitive system), putamen (motor system), and ventral striatum
(emotional/motivational system) [38,46–48]. This last part is
formed by the NAcb, which consists of a core (NAcbC) and a shell
(NAcbS). The core belongs to the extrapyramidal basal ganglia,
and is primarily involved in motivating the organism to exhibit
skilled behaviour. The shell belongs to the limbic basal ganglia
and is primarily involved in facilitating intuitive behaviour [38,48].
Only the most posterior part of the circuits is shown in Fig. 4. In
reality, in each circuit, information from different cortical areas
converges within the circuit to influence a specific point of the
frontal cortex [46,47]. This architecture also results in five segre-
gated cortical-subcortical re-entry circuits, one each for motor,
oculomotor, and executive lateral prefrontal function, and two
circuits (anterior cingulate and orbitofrontal) for emotional-
motivational functions [46,47]. The motivational re-entry circuit
runs through the NAcbC, which is activated by the anterior part
of the anterior cingulate cortex (aCg, BA24) and the orbitofrontal
cortex (e.g., BA11) [48–50]. Although not yet proven, an emotional
re-entry circuit could be postulated to exist with its first station in
the NAcbS, which is activated by the infralimbic subgenual cingu-
late (BA25) and the orbitofrontal cortex (Fig. 5). These last two
structures are essential for our depressive state model. Activation
of the NAcbC circuit results in behaviour that may finally result
in reward. This activation is accompanied with feelings, as exhib-
ited in a very pure (although pathological) form of ‘craving’ illicit
drugs [28]. Relief from this feeling may be postulated to be experi-
enced as ‘pleasure’ or ‘lust.’ Dysfunction of this circuit can be
expected to result in demotivation to exhibit rewarding behaviourthala
Fig. 4. Simplified representation of the posterior parts of three cortico-striato-thala
purple = glutamatergic; blue = GABAergic; grey = dopaminergic; VS = ventral striatum (l
pallidus, internal segment; VP = ventral pallidum; STh = subthalamic nucleus; SNc = sub
tegmental area.(lack of energy) and the inability to experience pleasure (anhedo-
nia). Activation of the NAcbS circuit leads to an unpleasant urge
to solve a significant problem [50]; the emotion that corresponds
to this behaviour is ‘unhappiness’ or ‘dysphoria’. According to this
hypothesis, depression as a ‘lust’ disorder is expected to be related
to hypo-activity of the NAcbC system, while depression as a ‘wor-
rying’ disorder is related to hyperactivity of the NAcbS circuit.
Two complementary circuit systems
We suggested distinguishing two types of basal ganglia: the
extrapyramidal basal ganglia (caudate nucleus, putamen,
NAcbC; blue in Fig. 6) and the limbic basal ganglia (NAcbS, bed
nucleus of stria terminalis, extended amygdala, central medial















mo-cortical circuits. Only connections of the putamen are shown. Red, orange,
argely accumbens nucleus); GPe = globus pallidus, external segment; GPi = globus
















Fig. 6. Model of the regulation of the extrapyramidal and limbic cortico-subcortical behaviour-regulating circuits. aCg = anterior cingulate cortex (Brodmann’s area (BA) 24);
blAmyg = basolateral amygdaloid complex; CC = corpus callosum; dlP9 = dorsolateral prefrontal cortex (BA9/46); EBG = extrapyramidal basal ganglia (caudate nucleus,
putamen, accumbens nucleus core); HC = hippocampus complex; LBG = limbic basal ganglia (accumbens nucleus shell, bed nucleus of the stria terminalis, extended
amygdala, centromedial amygdala); mP10 = dorsomedial prefrontal cortex (BA9/10); oF11 = orbitofrontal cortex (BA11); pCg = posterior cingulate cortex (BA23/31);
pmF6 = posterior dorsolateral prefrontal cortex (BA6); pto = parietal temporal occipital association cortex (BA22/39/40); sCG = subgenual cingulate cortex (BA25).
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system originates from the entire neocortex, including a few limbic
areas. This circuit runs from the cerebral cortex to the striatum and
finally through the dorsal thalamus to frontal (anterior) areas of
the cerebral cortex [46]. It consists of topographically arranged,
more or less segregated, converging circuits and contains the five
re-entry circuits described above [38]. We postulate the existence
of a second, limbic circuit system. This limbic circuit starts in allo-
cortical areas of the cerebral cortex, hippocampus complex [39],
and basolateral part of the amygdala and runs through the limbic
basal ganglia to the hypothalamus and (directly or thereafter) tha-
lamus. From there, some projections run to the mesial part of the
frontal cerebral cortex [13,51] and the insula [52].
As an interface between these systems, two circuits involving
the NAcbC and NAcbS are positioned (Fig. 5). It remains to be
demonstrated whether or not some of the fibres running through
the NAcbS are members of a sequential cortical-subcortical-
cortical re-entry circuit. The subgenual cingulate cortex (BA25)
receives thalamic afferents from the mediodorsal, paratenial, and
reuniens nuclei [53]. We postulate the existence of a circular causal
relationship between the dysfunctioning of limbic cortical circuits
as described by Mayberg and colleagues [41,42] and the two
cortical-basal ganglia-thalamic-frontal cortical circuits described
above.
The two circuits running through NAcbC and NAcbS are comple-
mentarily active and interact with each other in a yin-and-yang
fashion. The first motivates reward-seeking and the second
misery-fleeing behaviour.Implications: two interacting substrates for depression
Accepting this model of MDD, consisting of two components
that are regulated by different cortical-subcortical-cortical circuits,
offers interesting starting points for brain imaging research. Thereare many benefits of this hypothesis when we try to explain the
pathophysiology of clinical events of mood disorders. For example,
individual differences in the efficacy of antidepressants might
depend on the varying degrees of damage of these neuronal cir-
cuits of each patient. It would be interesting to study the acute
and chronic effects of more or less selective serotonergic (citalo-
pram), noradrenergic (reboxetine), and dopaminergic (modafinil)
antidepressants and certain specific receptor agonists or antago-
nists with neuroimaging techniques, specifically addressing these
anatomical structures in patients with the broadly defined depres-
sive disorder according to DSM-5. The NAcbS receives adrenergic
input from fibres coming from the locus coeruleus which stimulate
b-adrenoceptors (Fig. 5) [50,54]. Down-regulation of postsynaptic
b-adrenoceptors is a consistent and robust effect of chronic treat-
ment with most antidepressants, and this effect is accelerated by
co-treatment with SSRIs [55]. Thus, chronic treatment with antide-
pressants may result in decreasing the activity of the limbic re-
entry circuit and promoting the activity of the circuit, which
includes the NAcbC. In 1987, Den Boer et al. described that depres-
sive symptomatology reacted more efficaciously to clomipramine,
which has an adrenergic component, than to the SSRI fluvoxamine
when patients were treated for anxiety disorders [56]. The antide-
pressant effects of SSRIs may be related to down-regulation of 5-
HT2C receptors within other parts of the limbic circuit (most likely
the cortical amygdala and/or hippocampus). At the onset of treat-
ment, indirect activation of 5-HT2C receptors participates in the
anxiogenic effects of selective 5-HT reuptake inhibitors (SSRIs) as
well as their inhibition of sleep, sexual behaviour and appetite
[57]. This condition is also known as the ‘‘jitteriness/anxiety syn-
drome” [58]. Conversely, progressive down-regulation of 5-HT2C
receptors parallels the gradual onset of clinical efficacy of SSRIs
[57]. This down-regulation may result in decreased sensitivity to
fear- or stress-inducing input and decreased activity of the limbic
circuit, which may explain both the antidepressant and anxiolytic
activity of SSRIs.
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find out whether certain pharmacological interventions result in
preferential amelioration of symptoms related to dysfunction of
one of the two subcortical circuits in comparison to others, and
whether such effects are predicted by different biomarkers.
Immunological biomarkers may be more closely linked to hyper-
function of the limbic subcortical circuit because this system is
involved in motivation to escape from misery. Can specific sub-
types of depression (e.g., bipolar depression) be identified that
respond better to noradrenergic or dopaminergic drugs? Specific
receptor ligands to modulate the activity of the extrapyramidal
and limbic circuits are readily available, and this strategy may give
far quicker results than classical clinical trials. The mixed state of
bipolar patients might depend on the co-hyperactivity or co-
hypo-activity of these circuits.Regulation of activity
We have recently reviewed the literature covering how these
circuits developed during evolution [10]. It should be realized that
the first vertebrates, comparable to modern lampreys, had an
extrapyramidal system that is quite comparable to that of humans
[10,11]. However, the striatum of these creatures is best consid-
ered as the forerunner of the nuclear amygdala instead of the
human striatum. Moreover, the lamprey habenula–projecting glo-
bus pallidum, a structure not clearly identified in humans, regu-
lates the activity of dopaminergic projections from the midbrain
to the striatum by influencing a pathway via the habenula and fas-
ciculus retroflexus to the brainstem. We want to suggest that a
similar system has been maintained in humans regulating the
activity of the circuits motivating reward acquisition or escape
from misery [10].Conclusion: two interacting substrates for depression
According to our hypothesis (Fig. 6), two types of mechanisms
can induce symptoms of depression. Activation of the extrapyrami-
dal basal ganglia-containing circuit results in activation of the
appetitive motivation seeking-system, which then results in crav-
ing for food, water, warmth, sex, illicit drugs, or social gratification.
This process is accelerated by hyperactivity of a re-entry circuit
starting in the orbitofrontal cortex. Hypoactivity of this structure
prevents the individual from experiencing sudden relief from these
feelings, which is sensed as pleasure or lust. Hypoactivity, there-
fore, results in a lack of motivation and anhedonia as symptoms
of depression. Activation of the limbic basal ganglia-containing cir-
cuit results in an urge to find relief from distress induced by inter-
nal or environmental circumstances. These unpleasant feelings are
described as dysphoria or unhappiness. It is hypothesised that this
process is accelerated by hyperactivity within a re-entry circuit
starting in the subgenual anterior cingulate. These two circuits
do not function independently, and their activities are adjusted
to the current circumstances by a regulatory system involving
the habenula.Conflict of interest
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